According to CMS, U.S. healthcare payments will top an estimated $5 trillion per year by 2022. At such a growth rate, the importance of the payer perspective is increasing with every diagnosis.
Memphis, TN (PRWEB) September 17, 2015
Both the site and the new products have been “engineered to resolve the payer blind spot problem,” according to managing editor, Richard Sims. (More on our unique take on Theranos can be found below or on Di’s website—http://www.DisruptiveInsightsGroup.com.
Not understanding payer management dynamics would be like investing in indices without understanding the Fed’s perspective on the economy. Investing in healthcare without insight into the payer perspective can add drag to returns because payers are, in large part, a primary force in healthcare pricing. Reimbursement trends directly reflect (and in some cases portend) costs trends. Payers are constantly managing the tension between their limited resources (money) and the pricing and volume dynamics at play.
According to CMS, U.S. healthcare payments will top an estimated $5 trillion per year by 2022. At such a growth rate, the importance of the payer perspective is increasing with every diagnosis. However, healthcare stakeholders (e.g., investors and industry participants) continue to have blind spots regarding key aspects of payer dynamics like current and expected future management practices, therapy-specific risks and outlooks, and strategies for managing costs (prior authorization, limiting provider influence, raising co-payments, delaying reimbursements, negotiating discounts, etc.). Industry stakeholders are looking for real-world insights into these blind spots.
More and more, payers are using information from quality of care outcomes to guide their decision-making processes. A general understanding of payer perspectives on alternative reimbursement models is necessary. Meaningful insight into payer strategies for managing specific therapeutic categories is foundational. Analysts and fellow-researchers need targeted insights that track payers’ targeted interventions.
Influxes of unexpected costs will put health plans at risk, and could restrict access to other life-saving therapies. The “blank-check pricing” (lack of cost controls) stakeholders have long observed speaks to the importance of understanding the payer perspective. Payers are at the greatest risk for these escalating costs. Turning these blind spots into meaningful insights in the decision making process is Di’s mission.
In exchange for customer engagement, Di is offering up to investors and decision makers its network— a diverse group of medical directors for leading health plans, PBMs, ACOs, integrated networks and employer coalitions in the form of Payer Insights.
The first two reports are available now and they clarify these blind spots in Spinal Surgery and Hip/Knee Surgery.
Sims called the launch of the new site “a big step forward.” Prior to the launch of the new website, distribution of Di’s products was limited to 3rd party resellers. The website opens up completely new relationship possibilities. “The feedback from and interaction with our customers on our Theranos report has been fantastic,” said Sims, “We are continuing to expand our network of healthcare influencers and stakeholders. The launch of our website and Payer Insights, allows us extend these conversations and products to new customers in new areas of healthcare. We look forward to engaging our customers at every stage of the diligence process.”
At http://www.DisruptiveInsightsGroup.com, visitors will be able to explore the current and growing product set, and engage Di through the company’s fresh, value-added content. The company also works with customers directly: creating custom projects and pursuing suggestions for future coverage of therapeutic areas.
“At its core, Di’s product set is about helping our customers mitigate or eliminate their blind spots,” Sims stated. “We all have blind spots and we expend a great deal of mental energy and resources on them. We are excited about the opportunity to work with our customers, leveraging our robust network to help eliminate uncertainty.”
Payers are, by themselves, a leading indicator of pricing trends in healthcare. Payer perspectives are not the only variable in healthcare pricing equations, but they are always in the middle of it. Typically, the payer perspective has long been an estimated variable. Payer Insights help convert that variable into a constant, so to speak. The reports provide customers with deep and ongoing insight into management strategies for the specific therapeutic categories you are already watching (and some you may not be).
Some can’t see the forest for the trees. Others can’t see the trees for the forest. Disruptive Insights seeks to play an active role in resolving this dilemma.
Will Theranos Turn the Lab Industry Upside Down – A Di Deep Dive
We believe Theranos poses a significant threat to the lab industry. Their technology, company mission, partnerships and impressive resume of stakeholders have – and probably rightfully so – garnered a great deal of attention. This report explores the disruptive potential that Theranos presents to the lab industry and key topics like:
Scaling microfluidic technology
The impact of a real POC or “near-POC” solution
Theranos’ current and future go-to-market strategy and impact on pricing
Walgreens’ aspirations in the total healthcare delivery market (and how Theranos might enable that!)
What the emergence of Theranos is really telling us about the direction of the lab industry.
Interested parties can obtain a preview of this report on Di’s website as well as check our latest blog entries on this topic.
As value-based models become increasingly prevalent in the U.S., Di’s Payer Insights offer a highly-coveted view into the current and expected trends in payer management and reimbursements. These reports detail the impacts payer management has on particular therapeutic categories, and explain, contextualize and track payer behavior.
By leveraging Di’s network of medical directors at major health plans across the US, the company is bringing together in one report primary sources on the current and expected reimbursement outcomes in these therapeutic categories.
A few questions Di’s Payer Insights answer:
Are payers looking to increase management focus in a given therapy?
What are payer expectations for overall surgery costs for a therapy in the near future?
Will alternative reimbursements come to a therapy? How soon? To what degree?
Visit Di’s website—http://www.DisruptiveInsightsGroup.com—to download a Payer Insights preview, or to start a conversation with the team.